199 related articles for article (PubMed ID: 21874059)
1. The effect of oral management on the severity of oral mucositis during hematopoietic SCT.
Yamagata K; Arai C; Sasaki H; Takeuchi Y; Onizawa K; Yanagawa T; Ishibashi N; Karube R; Shinozuka K; Hasegawa Y; Chiba S; Bukawa H
Bone Marrow Transplant; 2012 May; 47(5):725-30. PubMed ID: 21874059
[TBL] [Abstract][Full Text] [Related]
2. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
3. Impact of oral care prior to HSCT on the severity and clinical outcomes of oral mucositis.
Santos PS; Coracin FL; Barros JC; Dulley FL; Nunes FD; Magalhães MG
Clin Transplant; 2011; 25(2):325-8. PubMed ID: 20482562
[TBL] [Abstract][Full Text] [Related]
4. A supersaturated calcium phosphate solution seems to effectively prevent and treat oral mucositis in haematopoietic stem cell transplanted cancer patients - single centre experience.
Wasko-Grabowska A; Rzepecki P; Oborska S; Barzal J; Mlot B; Gawronski K; Wasko M; Szczylik C
J BUON; 2012; 17(2):363-8. PubMed ID: 22740219
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation.
Kim KI; Kim JW; Lee HJ; Kim BS; Bang SM; Kim I; Oh JM; Yoon SS; Lee JS; Park S; Kim BK
Am J Hematol; 2013 Feb; 88(2):107-12. PubMed ID: 23225026
[TBL] [Abstract][Full Text] [Related]
6. Palifermin for prevention of oral mucositis after haematopoietic stem cell transplantation- single centre experience.
Rzepecki P; Sarosiek T; Barzal J; Oborska S; Nurzynski P; Wasko A; Szczylik C
J BUON; 2007; 12(4):477-82. PubMed ID: 18067205
[TBL] [Abstract][Full Text] [Related]
7. Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT--results of a multicentre study.
Vagliano L; Feraut C; Gobetto G; Trunfio A; Errico A; Campani V; Costazza G; Mega A; Matozzo V; Berni M; Alberani F; Banfi MM; Martinelli L; Munaron S; Orlando L; Lubiato L; Leanza S; Guerrato R; Rossetti A; Messina M; Barzetti L; Satta G; Dimonte V
Bone Marrow Transplant; 2011 May; 46(5):727-32. PubMed ID: 20818449
[TBL] [Abstract][Full Text] [Related]
8. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
Vokurka S; Bystricka E; Scudlova J; Mazur E; Visokaiova M; Vasilieva E; Brandejsova R; Chvojkova I; Vrabcova M; Vitkova J; Mjartanova D; Vodickova M; Bockova J; Streinerova K
Eur J Oncol Nurs; 2011 Dec; 15(5):508-12. PubMed ID: 21310656
[TBL] [Abstract][Full Text] [Related]
9. Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit.
Quinn B; Stone R; Uhlenhopp M; McCann S; Blijlevens N
Eur J Oncol Nurs; 2007; 11 Suppl 1():S10-8. PubMed ID: 17540294
[TBL] [Abstract][Full Text] [Related]
10. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
[TBL] [Abstract][Full Text] [Related]
11. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2.
Vokurka S; Steinerova K; Karas M; Koza V
Bone Marrow Transplant; 2009 Nov; 44(9):601-5. PubMed ID: 19349956
[TBL] [Abstract][Full Text] [Related]
13. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation.
Freytes CO; Ratanatharathorn V; Taylor C; Abboud C; Chesser N; Restrepo A; Arango J; Odenheimer D
Clin Cancer Res; 2004 Dec; 10(24):8318-24. PubMed ID: 15623608
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic stem cell transplantation.
Bezinelli LM; de Paula Eduardo F; da Graça Lopes RM; Biazevic MG; de Paula Eduardo C; Correa L; Hamerschlak N; Michel-Crosato E
Hematol Oncol; 2014 Mar; 32(1):31-9. PubMed ID: 23625880
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of erythropoietin mouthwash in prevention of oral mucositis in patients undergoing autologous hematopoietic SCT: a double-blind, randomized, placebo-controlled trial.
Hosseinjani H; Hadjibabaie M; Gholami K; Javadi M; Radfar M; Jahangard-Rafsanjani Z; Hosseinjani E; Shabani N; Vaezi M; Ghavamzadeh A
Hematol Oncol; 2017 Mar; 35(1):106-112. PubMed ID: 26310513
[TBL] [Abstract][Full Text] [Related]
17. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial.
Jahangard-Rafsanjani Z; Gholami K; Hadjibabaie M; Shamshiri AR; Alimoghadam K; Sarayani A; Mojtahedzadeh M; Ostadali-Dehaghi M; Ghavamzadeh A
Bone Marrow Transplant; 2013 Jun; 48(6):832-6. PubMed ID: 23292233
[TBL] [Abstract][Full Text] [Related]
19. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
Sugita J; Matsushita T; Kashiwazaki H; Kosugi M; Takahashi S; Wakasa K; Shiratori S; Ibata M; Shono Y; Shigematsu A; Obara M; Fujimoto K; Endo T; Nishio M; Kondo T; Hashino S; Tanaka J; Asaka M; Imamura M
Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
